Hiligsmann M, et al. - This research was attempted to evaluate the cost-effectiveness of sequential treatment with abaloparatide (ABL) followed by alendronate (ALN) [(ABL/ALN)] compared with ALN monotherapy and to sequential treatment starting with antiresorptive therapy (ALN/ABL/ALN). Researchers applied a previously validated Markov microsimulation model to calculate the cost-effectiveness of sequential ABL/ALN compared with ALN monotherapy and to sequential ALN/ABL/ALN from a lifetime US payer perspective. This study performed an evaluation for individuals aged 50-80 years old with a BMD T-score ≤ -3.5 and without a history of prior fracture, or with a T-score between -2.5 and -3.5 and a history of ≥ 1 osteoporotic fracture. The results of this study demonstrated that sequential ABL/ALN therapy is cost-effective vs ALN monotherapy for US postmenopausal women aged ≥ 60 years at increased risk of fractures.